Compare Endeavour Silver Corp (EXK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Recursion Pharmaceuticals Inc — how do they compare? Endeavour Silver Corp trades at $8.84 (market cap $2.46B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Endeavour Silver Corp and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is more actively traded (40,478,768 versus 5,827,665). Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EXK | RXRX | |
|---|---|---|
Market Cap | $2.46B | $2.31B |
Volume | 5,827,665 | 40,478,768 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $6.79 |
52-Week Low | $7.07 | $2.84 |
Typical Hold Time | 25 Days | 22 Days |
Enterprise Value | $2.47B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.32, down 4.04% on the day, amid a bearish technical signal. The company reported a net loss of $119.1M in 2025 but expects a significant turnaround in 2026 with projected net income of $66M. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions have occurred. Analyst consensus is strongly bullish with a $10.50 price target, but technical indicators show selling pressure.
The outlook is mixed: strong analyst support and projected profitability in 2026 present upside, but near-term technical weakness and operational risks like mine blockades pose challenges. The stock's valuation multiples are elevated relative to current earnings, requiring successful execution of growth plans to justify further gains.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
